
Propanc Biopharma fell 90.0% from $18.90 to $1.89, behind the S&P 500's +11.2%. Its worst day was Aug 28 (−39.5%), and its low came Oct 22 at $0.27.
Story events cover the past 12 months · Times ET
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-9.75 was reported on $0.00 revenue.
0.0% · S&P 500 −0.9%
Propanc Biopharma closed at its highest level of the year, 24.7% above where the year started.
+5.5%
EPS of $-7.50 was reported on $0.00 revenue.
+3.2% · S&P 500 +0.2%
EPS of $-7.00 was reported on $0.00 revenue.
−6.8% · S&P 500 −1.2%
EPS of $-0.10 was reported on $0.00 revenue.
−4.0% · S&P 500 −0.2%
Propanc Biopharma closed at its lowest level of the year, 98.5% below where the year started.
−13.1% · S&P 500 −1.2%
EPS of $-12.22 was reported.
−3.6% · S&P 500 −1.9%
Where it ended: a close of $1.89 on Nov 16, 2026. Up next: Q2 2027 earnings on Feb 16, 2027.
Nothing in the past 12 months.
All PPCB analyst actionsNothing in the past 12 months.
All PPCB dividend history